RxDoctor Payments Data

Alan Shapiro, DO

Emergency Medicine · Pittsburgh, PANPI 1073713921

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $33,525 of the $36,873 with a category attached, or 90.9%. 9 manufacturers reported payments, led by AstraZeneca at 41.0% of the total. Reporting peaked in 2019 at $11,969 and has fallen 70.2% since, to $3,570 in 2024. Among emergency medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,873in general payments, 2019–2025

Across 69 payments — averaging $534.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • E.r. Squibb & Sons, L.L.C.$11K
  • Pfizer$7K
  • Portola Pharmaceuticals, LLC$3K
  • CSL Behring$123
  • BTG International Inc.$59
  • plus $111 from 3 others

What the payments were for

  • Consulting fees$5001%
  • Speaking & faculty fees$33,52591%
  • Travel & lodging$1,2513%
  • Food & beverage$1,5884%
  • Education$90%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,873 in reported general payments places this provider in the 95th percentile of 3,120 emergency medicine providers in Pennsylvania.

See all emergency medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$120,841
Medicare patients
740
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$10,258
Ondansetron OdtOndansetron91$956
Oxycodone Hcl176$560
Albuterol Sulfate HfaAlbuterol Sulfate17$535
Cephalexin51$499
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav65$447
Methylprednisolone45$222
Dexamethasone21$177
Clindamycin Hcl11$164
Methocarbamol31$156
Prednisone59$122
Meclizine Hcl30$105
Tamsulosin Hcl11$56
Azithromycin13$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$7,417$10,25815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,120 emergency medicine providers in Pennsylvania.

Other emergency medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →